<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726750</url>
  </required_header>
  <id_info>
    <org_study_id>PA15-0575</org_study_id>
    <secondary_id>NCI-2020-07336</secondary_id>
    <secondary_id>PA15-0575</secondary_id>
    <nct_id>NCT02726750</nct_id>
  </id_info>
  <brief_title>Clinical and Genomic Predictors of Progression to Myeloma in Patients With Asymptomatic Monoclonal Gammopathies</brief_title>
  <official_title>Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to find markers that may help to predict why some patients who have&#xD;
      monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM)&#xD;
      that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while&#xD;
      others do not. Studying markers such as age, level of proteins in blood, percent of abnormal&#xD;
      blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may&#xD;
      help researchers to validate clinical and genomic predictors for future use in clinical&#xD;
      practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the rate of progression to multiple myeloma after 3 years of follow up.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe baseline patient characteristics and clinical variables. II. To identify&#xD;
      molecular and genetic correlates that may predict for progression to multiple myeloma (MM).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo collection of blood samples every 6 months for 3 years. Patients may also&#xD;
      undergo a biopsy, x-rays, positron emission tomography (PET)/computed tomography (CT) scans,&#xD;
      and/or magnetic resonance imaging (MRI) scans to check the status of disease at the&#xD;
      discretion of the treating physician.&#xD;
&#xD;
      After completion of 3 years on study, patients are followed up every 6-12 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2015</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of progression to multiple myeloma (MM)</measure>
    <time_frame>3 years</time_frame>
    <description>Kaplan-Meier method will be used to estimate time to MM progression. Log-rank test will be used to evaluate the difference in rate of progression between/among patient groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method. Log-rank test will be used to evaluate the difference in rate of progression free survival between/among patient groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method. Log-rank test will be used to evaluate the difference in rate of overall survival between/among patient groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline patient characteristics and clinical variables</measure>
    <time_frame>Baseline</time_frame>
    <description>Summary statistics including mean, standard deviation, median, and range will be provided for continuous variables. Frequency counts and percentages will be used to summarize categorical variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular and genetic profile analysis</measure>
    <time_frame>3 years</time_frame>
    <description>Will study the correlation of molecular and genetic profiles with time to MM progression.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Molecular profiling analysis of patients who develop MM</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis will include whole exome sequencing and gene expression profiling and cellular (including flow cytometry) profiling using bone marrow and peripheral blood samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune characterization of patients who develop MM</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis will include cell surface and functional studies of dendritic, T-, B-, natural killer (NK)- and NKT-cells using peripheral blood samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune characterization of patients who develop MM</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis will include cell surface and functional studies of dendritic, T-, B-, NK- and NKT-cells using bone marrow samples.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Monoclonal Gammopathy of Undetermined Significance</condition>
  <condition>Smoldering Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Observational (biospecimen collection)</arm_group_label>
    <description>Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Observational (biospecimen collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Observational (biospecimen collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, bone marrow&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with monoclonal gammopathy of unknown significance and/or smoldering multiple&#xD;
        myeloma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with monoclonal gammopathy of unknown significance. Both criteria must be&#xD;
             met:&#xD;
&#xD;
               -  Serum monoclonal protein &lt; 3 g/dL or urinary monoclonal protein &lt; 500 mg per 24&#xD;
                  hours and clonal bone marrow plasma cells &lt; 10%&#xD;
&#xD;
               -  Absence of myeloma defining events or amyloidosis&#xD;
&#xD;
          -  Patients with smoldering multiple myeloma. Both criteria must be met:&#xD;
&#xD;
               -  Serum monoclonal protein &gt;= 3 g/dL or urinary monoclonal protein &gt;= 500 mg per 24&#xD;
                  hours and/or clonal bone marrow plasma cells 10-60%&#xD;
&#xD;
               -  Absence of myeloma defining events or amyloidosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of myeloma defining events or biomarkers of malignancy due to underlying&#xD;
             plasma cell proliferative disorder meeting at least one of the following&#xD;
&#xD;
               -  Hypercalcemia: serum calcium &gt; 0.25 mmol/L (&gt; 1 mg/dL) higher than the upper&#xD;
                  limit of normal or &gt; 2.75 mmol/L (&gt; 11 mg/dL)&#xD;
&#xD;
               -  Renal Insufficiency: creatinine clearance &lt; 40 ml/min or serum creatinine &gt; 2&#xD;
                  mg/dL&#xD;
&#xD;
               -  Anemia: hemoglobin value &lt; 10 g/dL or 2 g/dL &lt; normal reference&#xD;
&#xD;
               -  Bone lesions: one or more osteolytic lesions on skeletal radiography,&#xD;
                  computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron&#xD;
                  emission tomography CT (PET-CT)&#xD;
&#xD;
               -  Clonal bone marrow plasma cell percentage &gt;= 60%&#xD;
&#xD;
               -  Involved:uninvolved serum free light chain ratio &gt;= 100 measured by Freelite&#xD;
                  assay (The Binding Site Group, Birmingham, United Kingdom [UK])&#xD;
&#xD;
               -  &gt; 1 focal lesions on magnetic resonance imaging (MRI) studies (each focal lesion&#xD;
                  must be 5 mm or more in size)&#xD;
&#xD;
          -  Prior or concurrent systemic treatment for asymptomatic monoclonal gammopathies&#xD;
&#xD;
               -  Bisphosphonates are permitted&#xD;
&#xD;
               -  Radiotherapy is not permitted&#xD;
&#xD;
               -  Prior treatment with chemotherapy or investigational agents for asymptomatic&#xD;
                  gammopathies is not permitted&#xD;
&#xD;
          -  Plasma cell leukemia&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including but not limited to active infection or&#xD;
             psychiatric illness/social situations that would compromise compliance with study&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabet E Manasanch</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei Huang</last_name>
    <phone>713-745-9901</phone>
    <email>mhuang3@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Huang</last_name>
      <phone>713-745-9901</phone>
      <email>mhuang3@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Elisabet E. Manasanch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Smoldering Multiple Myeloma</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

